Skip to main content
Signal8
Launch Terminal

Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Avalyn Pharma Inc. Common Stock logo

Avalyn Pharma Inc. Common Stock

NASDAQ:AVLNHealthcare
-0.31%$25.63
AH$25.18-1.76%vs close
Mkt Cap$1.14B
Float20.32M
O/S44.33M
Vol
$ Vol
RVOL
Inst Own91.3%
SI11.6%
Earnings
Dilution
Avalyn Pharma Inc. Common Stock logoNASDAQ:AVLN$25.63-0.31%
FormDescription
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
8-K
5.02
13G
Beneficial Ownership Report
10-Q
Quarterly Report
8-K
2.02,9.01
13G
Beneficial Ownership Report
13G/A
Beneficial Ownership Report (Amended)
8-K
1.01,9.01
8-K
7.01
10-Q
Quarterly Report
8-K
2.02,9.01
13D
Beneficial Ownership Report (Active)
13D
Beneficial Ownership Report (Active)
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership

1-25 of 63